Highlight
Venetoclax resistance remains a significant challenge in treating acute myeloid leukemia (AML). Recent research identifies protein arginine methyltransferase 9 (PRMT9) as a key mediator of this resistance by modulating RNA splicing and translation. Inhibition of PRMT9 restores venetoclax sensitivity in resistant AML models, suggesting a novel therapeutic strategy.
